@farid__jalali @zzz_as_zzz Direct contact with NETs is also an inflammasome trigger in its own right. https://t.co/LdOrNkwrVK
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
@csentropy @tromover Anakinra can largely mute the response to inflammasome-mediated IL-1β release from the pyroptosis of infected macrophages and T-lymphocytes or their encounters with NETs (which also trigger it). Generally very good feedback on that on
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
Yet another retrospective study showing how critical is blocking inflammation during #covid19: this time Interleukin-1 blockade with high-dose anakinra @TheLancetRheum https://t.co/8RcQaN0q8F
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/WhsT1OOAC7
The arthritis drug #Anakinra appears to be safe and effective for treating #COVID19-related inflammation https://t.co/opCzjtux8M https://t.co/TMYsVEnEVk
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/p0d3U3y4vQ
RT @DrAnimeshSingh: Two different #anakinra in #COVID19 studies published recently. Is there a ‘correct’ dose & route of administration fo…
Editor’s Choice for #EULAR2020—Interleukin-1 blockade with high-dose #anakinra in patients with #COVID19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/de5T0E3hLD #LancetRheumatology https://t.co/j4Z7
RT @psyberocket: LancetRheumatol https://t.co/tRZR1XCOy8 抗リウマチ薬併用で重症COVID-19が改善 イタリア・コホート研究 ICU以外で治療を受けているCOVID-19重症患者にIL-1受容体拮抗薬anakinra…
@STEMthebleeding Re: "CS symptoms are present, right?" Should be for blocking IL-1 signaling, to limit cytokine storm. You're right; I think it makes sense to hold enough until symptoms. Blocking IL-1 signaling too early for no good reason is a bad idea.
PaperOfTheDay "Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study" https://t.co/9QlIebVB3T https://t.co/60SpamXTPx
RT @BiotechMania: ARDSを合併するCOVID19に高用量アナキンラ(IL-1受容体拮抗、リウマチを適応に欧米で承認) が有望かも、との後ろ向き研究。 サイトカインストームをアクテムラ、ケブザラ(抗IL-6抗体)で抑えるのが必ずしもよい臨床結果ではなさそうな中…
RT @giovannilandoni: We administered high doses anakinra in 29 patients with severe bilateral #COVID19 pneumonia (but not yet admitted to t…
@jambuc33 @gpollara
Two different #anakinra in #COVID19 studies published recently. Is there a ‘correct’ dose & route of administration for Anakinra in hyperinflammatory states? https://t.co/2wndslmvCb https://t.co/QNPxLIvtrk
L'#anakinra, un inhibiteur d'IL-1, testé dans les formes sévères de Covid-19 par une équipe française https://t.co/Rqzmb0VTO3 Après une équipe italienne https://t.co/Xd303CyeMj
Another anakinra study Anakinra for severe forms of #COVID19: cohort study Perhaps a signal here in sick patients, but will need RCTs https://t.co/j2lZhqX3oB https://t.co/Skx6XU53uB
RT @DrGomi: anakinra chez les patients graves , étude italienne, signal positif demandant confirmation https://t.co/F8FmXPC5gU
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study #COVID19 #Anakinra #ARDS #hyperinflammation https://t.co/KiHgJF8oAO
RT @dlmetcalf: @MartyMoore_Vax @Outoftweet123 @profvrr @Globerunner31Uk Marty, I still haven't seen an RCT, but this is an interesting retr…
Encouraging outcomes with anakinra in this retrospective experience of patients with high CRP and ARDS with COVID. Several prospective trials will define the utility of anakinra in SARS-2-covid inflammatory lung disease. https://t.co/4lMBoaCaIj #covid19 #
当然ながらサイトカインストームにはIL-1遮断は有効ですよね。これで臨床データもできました。 QT: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/wiR4eRABMt
Interleukin-1 blockade #IL1 with high-dose #anakinra in patients with #COVID19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/n7uSz6FjwZ
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
anakinra for covid 19 cytokine storm?? https://t.co/eLnhYsHw8c
サイトカインストームなのね、重症コロナは Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/TfsecpwyEE
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
@correfrotinha corticoide, corticoide, corticoide. tem um outro remédio promissor mas, infelizmente, não parecem estar usando nas crianças https://t.co/SyyaZoaTBS
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/v50oSMqi66
RT @Sandy95455811: @niro60487270 Italy has success treating moderate-to-severe ARDS and hyperinflammation, combining HCQ with lopinavir, ri…
RT @TheLancetRheum: ICYMI
RT @Sandy95455811: @niro60487270 Italy has success treating moderate-to-severe ARDS and hyperinflammation, combining HCQ with lopinavir, ri…
RT @Sandy95455811: @niro60487270 Italy has success treating moderate-to-severe ARDS and hyperinflammation, combining HCQ with lopinavir, ri…
RT @Sandy95455811: @niro60487270 Italy has success treating moderate-to-severe ARDS and hyperinflammation, combining HCQ with lopinavir, ri…
RT @Sandy95455811: @niro60487270 Italy has success treating moderate-to-severe ARDS and hyperinflammation, combining HCQ with lopinavir, ri…
RT @TheLancetRheum: ICYMI
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Interesting retrospective comparison of #anakinra (IL-1RA) with historical (previous week) cohort treated with (new standard therapy), showing a potential promise that requires a CRT to confirm in the treatment of #COVID19 DOI:https://t.co/VN9kfTOBmD
RT @TheLancetRheum: ICYMI https://t.co/rPQvXJcnmf
https://t.co/WFk1bbQ7P4 New low standard.
#COVID19 #新型肺炎 ICU外の人工呼吸器患者にアナキンラ大量静注が効果あり "Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study", Lancet, 2020/5/7 https://t.co/nMJZividrr
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
ICYMI
🔝Interleukin-1 blockade with high-dose #anakinra in patients with #COVID19, acute respiratory distress syndrome, and hyperinflammation » https://t.co/FnRmKNp59c Treatment with high-dose anakinra was safe and associated with clinical improvement in 72% of p
High-dose intravenous anakinra quenched hyper-inflammation, improved respiration, and reduced death and need for ICU admission in COVID-19 acute respiratory distress syndrome. Read more here: https://t.co/TNUaV4LgTD
RT @AbbateAntonio: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyper…
RT @SRAnesthesiaICU: In this retrospective study of #COVID19 patients with ARDS managed with non-invasive ventilation outside ICU, high-dos…
Here's the article in The Lancet https://t.co/eRsDC9Z2JH
Promising #COVID19 trial data with #anakinra (IL-1RA) coming out out Italy, hinting towards a neutrophil-driven pathogenic mechanism. https://t.co/kiXNen1Uzm https://t.co/R4Z3FquX6W
Time to do a RCT for Anakinra. @JMRocco5 https://t.co/0cTUX9SqJX
RT @giovannilandoni: We administered high doses anakinra in 29 patients with severe bilateral #COVID19 pneumonia (but not yet admitted to t…
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…
Cavalli G et al: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study #COVID19 https://t.co/i8N8536eco
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…
Cold take: results coming in from trials in category of agents more intuitively likely to be useful in severe #COVID19 — anti inflammatories! https://t.co/NEVb3ruMS5
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/1VkJ960Vl7
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…
https://t.co/Lz3IzjbNTN Small study from Italy in COVID-19 pts w ARDS/cytokine storm rx'd w high dose IL-1 blockade (anakinra) + HCQ, antiviral rx & non-mechanical ventilation-found improved survival benefit (72%) w reduced need for mechanical ventilat
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @GravelJocelyn: Étude rétrospective avec tous les risques de biais que cela engendre. Un anti-inflammatoire (Anakinra) chez les patients…
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…
RT @ArmelleID: Interleukin-1 blockade with high-dose anakinra in patients with #COVID19 Retrospective cohort study Anakinra was associat…
RT @ABsteward: In this small retrospective cohort study @TheLancetRheum of patients with #COVID19 and ARDS managed with non-invasive ventil…
RT @nursemaiden: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperin…
RT @profgeraintrees: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyp…
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/8DciR10nCy
Fantastic to think that Anikinra my son’s treatment for his hyper inflammation rare disease is showing promising results for #COVID19 CoVID19. Its been life changing for him 👍
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study - The Lancet Rheumatology https://t.co/jD5e2wpjGx
RT @ABsteward: In this small retrospective cohort study @TheLancetRheum of patients with #COVID19 and ARDS managed with non-invasive ventil…
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…
RT @LancetRespirMed: Article published in @TheLancetRheum is the first retrospective cohort study to describe IL-1 blockade with high-dose…